The 2012 Investor Forum was the 3rd annual event organized by the NCI SBIR program to connect some of the most promising SBIR Awardees with the external investors and strategic partners that are critical to the awardees moving their technologies towards the marketplace. The most recent Investor Forum was held at Stanford University on November 9th, 2010. 14 NCI SBIR awardees were selected to present at the 2010 forum and there were over 200 attendees including about 150 representatives of the investment and biotech firms. Attendees included high level professionals from Big Pharma, VaC firms, Angel investors, large banks, disease foundations, etc. Four significant investment/partnership deals that were signed as a result of interactions at the forum and a number of discussions are ongoing. Thus, the success of the 2010 forum has strengthened interest in going back to the Bay Area for this year’s forum.
The Investor Forum was an exclusive event designed to connect the strongest and most promising NCI SBIR companies with life science investors and strategic partners. In 2010, relationships established at the NCI SBIR Investor Forum resulted in more than $225 million in deals to advance companies on the cutting-edge of cancer technology development.

Highlights of this full-day conference include:

• Sneak preview of the top 10-15 early-stage oncology companies currently funded by the NCI and learn about some of the latest cancer technology and therapeutic developments.
• 200 investors, venture capitalists, deal-makers, scientists, and small business leaders from the biotech and pharmaceutical industries.
• Private breakout sessions and a networking reception with featured companies.
• Meet one-on-one with NCI leadership to gain new insights on funding and partnership opportunities and hear updates on new programs to accelerate promising cancer-related technologies to commercialization.

For more information about the 2012 NCI SBIR Investor Forum, please go to this website: http://sbir.cancer.gov/investorforum/

Sponsors:

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization with more than twenty years experience providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, AMRI maintains geographic proximity and flexible cost models.	Janssen Research & Development (JRD) has created Janssen Labs to provide state of the art space and equipment in a flexible environment to help companies further develop their business more efficiently. Occupant companies of Janssen Labs have access to flexible modular wet lab units and only pay for the space that they need. And should there be a need to expand, the flexibility within Janssen Labs allows the ability to move into a larger space, quickly.
Merck & Co., Inc. is an innovative, global healthcare leader that is committed to improving health and well-being around the world. Our product offering categories include heart and respiratory health, infectious diseases, sun care and women's health. We continue to focus our research on conditions that affect millions of people around the world - diseases like Alzheimer's, diabetes and cancer - while expanding our strengths in areas like vaccines and biologics. We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them. At Merck, we're applying our global reach, financial strength and scientific excellence to do more of what we're passionate about: improving health and improving lives.	Entrepreneurs look beyond the status quo and innovate. They want like-minded partners to provide venture capital funding, connections and startup experience. That's where Mohr Davidow comes in. Together, we create venture returns by moving innovation forward and bringing new, technology-based ideas, products and services to market.
Imagine lawyers who are as interested in what you do as you are. Who understand the value of your new technology or new product or new transaction. Who are prepared to work with you to create it, protect it and maximize your opportunity to derive value from it. Who'll help you to bring it to fruition, or finance it, or bring it to market, or sell it. And, who are prepared to zealously defend it – in or out of court. Imagine lawyers with imagination. This is MoFo.

For more information, please contact aashby [at] fnih [dot] org (Ann Ashby, Deputy Executive Director), aashby [at] fnih [dot] org, Sponsorships and Corporate Relations Foundation for the National Institutes of Health